Chinese CRO ShangPharma one step closer to going private

As the U.S.'s largest CRO seeks an IPO, one of China's heavyweights is moving in the opposite direction. ShangPharma ($SHP) is putting its plans to go private in front of shareholders on March 20, asking for approval on a deal that would sell the company to a group of private equity outfits for $173 million. The CRO's client list includes major drugmakers like Eli Lilly ($LLY) and GlaxoSmithKline ($GSK). Item

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.